Ashley
Lv11
30 积分
2023-12-20 加入
-
推进创新药同步研发,注册与审评,构建中国医药创新生态系统——重要意义及总体建议
3天前
已完结
-
Chinese innovative drug R&D trends in 2024
3天前
已完结
-
Newly approved cancer drugs in China — innovation and clinical benefit
3天前
已完结
-
Challenges and opportunities in oncology drug development and clinical research in China
8天前
已关闭
-
Cancer incidence and mortality in China, 2022
8天前
已完结
-
Brief Report: Evaluating the Impact of Perioperative Immune Checkpoint Inhibitor in the Treatment of Patients with Resectable Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
18天前
已完结
-
Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study
1个月前
已完结
-
Envonalkib versus crizotinib for treatment-naive ALK-positive non-small cell lung cancer: a randomized, multicenter, open-label, phase III trial
2个月前
已关闭
-
Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial
2个月前
已完结
-
Perioperative Nivolumab in Resectable Lung Cancer
2个月前
已完结